scholarly journals Marine natural products

2017 ◽  
Vol 34 (3) ◽  
pp. 235-294 ◽  
Author(s):  
John W. Blunt ◽  
Brent R. Copp ◽  
Robert A. Keyzers ◽  
Murray H. G. Munro ◽  
Michèle R. Prinsep
Keyword(s):  
Natural Products ◽  
Absolute Configuration ◽  
Marine Natural Products ◽  
Cancer Drug ◽  
Anti Cancer ◽  
New Compounds

This review of marine natural products for 2015 describes 1340 new compounds and reports structural revisions or assignments of absolute configuration for previously reported compounds. Other aspects of marine natural products research over the three sesquidecades from 1971 are also examined and contrasted against the 2015 discovery of the source of ET-743, also known as the anti-cancer drug Yondelis®(trabectedin).

scholarly journals Marine natural products

2016 ◽  
Vol 33 (3) ◽  
pp. 382-431 ◽  
Author(s):  
John W. Blunt ◽  
Brent R. Copp ◽  
Robert A. Keyzers ◽  
Murray H. G. Munro ◽  
Michèle R. Prinsep
Keyword(s):  
Natural Products ◽  
Absolute Configuration ◽  
Marine Natural Products ◽  
New Compounds

This review of marine natural products for 2014 describes 1378 new compounds and reports structural revisions or assignments of absolute configuration for previously reported compounds. Since 1965 MNP chemists have made ∼9000 collections worldwide yielding ∼25 700 new MNPs. The rate of discovery of MNPs by region is examined in this review.

scholarly journals Marine natural products

2015 ◽  
Vol 32 (2) ◽  
pp. 116-211 ◽  
Author(s):  
John W. Blunt ◽  
Brent R. Copp ◽  
Robert A. Keyzers ◽  
Murray H. G. Munro ◽  
Michèle R. Prinsep
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Phase I ◽  
Marine Natural Products ◽  
Rapid Development ◽  
Phase I Clinical Trials ◽  
New Compounds

This review of marine natural products for 2013 describes 1137 new compounds and reports structural revisions and assignments of absolute configurations for previously described compounds. Included is a report of the anticancer sponge metabolite PM060184 that has undergone a remarkably rapid development from discovery in 2005 to the commencement of phase I clinical trials in 2011.

scholarly journals Defining desirable natural product derived anticancer drug space: optimization of molecular physicochemical properties and ADMET attributes

ADMET & DMPK ◽  
2016 ◽  
Vol 4 (2) ◽  
pp. 98 ◽  
Author(s):  
Deepika Singh
Keyword(s):  
Hydrogen Bond ◽  
Natural Products ◽  
Physicochemical Properties ◽  
Natural Product ◽  
Aqueous Solubility ◽  
Cancer Drug ◽  
Log P ◽  
Drug Candidates ◽  
Anti Cancer ◽  
Property Space

<p class="ADMETabstracttext">As part of our endeavor to enhance survival of natural product derived drug candidates and to guide the medicinal chemist to design higher probability space for success in the anti cancer drug development area, we embarked on a detailed study of the property space for a collection of natural product derived anti cancer molecules. We carried out a comprehensive analysis of properties for 24 natural products derived anti cancer drugs including clinical development candidates and a set of 27 natural products derived anti cancer lead compounds. In particular, we focused on understanding the interplay among eight physicochemical properties including like partition coefficient (log P), distribution coefficient at pH=7.4 (log D), topological polar surface area (TPSA), molecular weight (MW), aqueous solubility (log S), number of hydrogen bond acceptors (HBA), number of hydrogen bond donors (HBD) and number of rotatable bonds (n<sub>Rot</sub>) crucial for drug design and  relationships between physicochemical properties, ADME (absorption, distribution, metabolism, and elimination) attributes, and in silico toxicity profile for these two sets of compounds. This analysis provides guidance for the chemist to modify the existing natural product scaffold or designing of new anti cancer molecules in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</p>

scholarly journals Acetylenic Synthetic Betulin Derivatives Inhibit Akt and Erk Kinases Activity, Trigger Apoptosis and Suppress Proliferation of Neuroblastoma and Rhabdomyosarcoma Cell Lines

2021 ◽  
Vol 22 (22) ◽  
pp. 12299
Author(s):  
Sylwia K. Król ◽  
Ewa Bębenek ◽  
Magdalena Dmoszyńska-Graniczka ◽  
Adrianna Sławińska-Brych ◽  
Stanisław Boryczka ◽  
...  
Keyword(s):  
Cell Cycle Progression ◽  
Cancer Drug ◽  
Drug Candidate ◽  
Cycle Progression ◽  
Oncological Treatment ◽  
Anti Cancer ◽  
New Compounds ◽  
Anti Tumor Activity ◽  
Reduced Activity

Neuroblastoma (NB) and rhabdomyosarcoma (RMS), the most common pediatric extracranial solid tumors, still represent an important clinical challenge since no effective treatment is available for metastatic and recurrent disease. Hence, there is an urgent need for the development of new chemotherapeutics to improve the outcome of patients. Betulin (Bet), a triterpenoid from the bark of birches, demonstrated interesting anti-cancer potential. The modification of natural phytochemicals with evidenced anti-tumor activity, including Bet, is one of the methods of receiving new compounds for potential implementation in oncological treatment. Here, we showed that two acetylenic synthetic Bet derivatives (ASBDs), EB5 and EB25/1, reduced the viability and proliferation of SK-N-AS and TE671 cells, as measured by MTT and BrdU tests, respectively. Moreover, ASBDs were also more cytotoxic than temozolomide (TMZ) and cisplatin (cis-diaminedichloroplatinum [II], CDDP) in vitro, and the combination of EB5 with CDDP enhanced anti-cancer effects. We also showed the slowdown of cell cycle progression at S/G2 phases mediated by EB5 using FACS flow cytometry. The decreased viability and proliferation of pediatric cancers cells after treatment with ASBDs was linked to the reduced activity of kinases Akt, Erk1/2 and p38 and the induction of apoptosis, as investigated using Western blotting and FACS. In addition, in silico analyses of the ADMET profile found EB5 to be a promising anti-cancer drug candidate that would benefit from further investigation.

Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells

2020 ◽  
Vol 27 ◽  
Author(s):  
Catarina Vizetto-Duarte ◽  
Pedro Castelo Branco ◽  
Luísa Custódio
Keyword(s):  
Stem Cells ◽  
Natural Products ◽  
Cancer Stem Cells ◽  
Marine Natural Products ◽  
Epithelial To Mesenchymal Transition ◽  
Heart Diseases ◽  
The Body ◽  
Mesenchymal Transition ◽  
Anti Cancer ◽  
Promising Source

: Cancer is the world’s second leading cause of death after heart diseases, and involves abnormal cell growth at a primary site and the potential to spread to other parts of the body. Tumors are highly heterogeneous and consist of subgroups of cells with distinct characteristics. Of these, the cancer stem cells (CSC) niche plays a crucial role in driving the spread of the tumor and are thought to provide treatment resistance. CSC is a rare special population of cancer cells exhibiting high tumorigenic properties together with self-renewal and differentiation capability. CSC is not only linked with high tumor-initiating activity, but is also implicated in chemotherapeutic re-sistance, metastasis, epithelial to mesenchymal transition, and recurrence. Thereafter, novel ther-apeutic strategies targeting CSC are in need in order to improve long-term clinical outcome. The literature supports the evidence that marine natural compounds can exhibit antioxidant, antimitot-ic, anti-inflammatory, anti-biotic as well as anticancer activity. In this review, we will provide an insight into the relevance of selected marine natural products as a source of bioactive compounds with anti-cancer properties, and to target CSC, which may benefit the development of novel anti-cancer therapeutic strategies.

scholarly journals Cembranoids of Soft Corals: Recent Updates and Their Biological Activities

2021 ◽  
Author(s):  
Marsya Yonna Nurrachma ◽  
Deamon Sakaraga ◽  
Ahmad Yogi Nugraha ◽  
Siti Irma Rahmawati ◽  
Asep Bayu ◽  
...  
Keyword(s):  
Natural Products ◽  
Natural Product ◽  
Biological Activities ◽  
Marine Natural Product ◽  
Soft Corals ◽  
Potential Health ◽  
Ecological Benefits ◽  
Natural Product Research ◽  
Anti Cancer ◽  
New Compounds

Abstract Soft corals are well-known as excellent sources of marine-derived natural products. Among them, members of the genera Sarcophyton, Sinularia, and Lobophytum are especially attractive targets for marine natural product research. In this review, we reported the marine-derived natural products called cembranoids isolated from soft corals, including the genera Sarcophyton, Sinularia, and Lobophytum. Here, we reviewed 72 reports published between 2016 and 2020, comprising 360 compounds, of which 260 are new compounds and 100 are previously known compounds with newly recognized activities. The novelty of the organic molecules and their relevant biological activities, delivered by the year of publication, are presented. Among the genera presented in this report, Sarcophyton spp. produce the most cembranoid diterpenes; thus, they are considered as the most important soft corals for marine natural product research. Cembranoids display diverse biological activities, including anti-cancer, anti-bacterial, and anti-inflammatory. As cembranoids have been credited with a broad range of biological activities, they present a huge potential for the development of various drugs with potential health and ecological benefits. Graphic Abstract

Sign in / Sign up

Export Citation Format

Share Document